Invitation to the MorphoSys 2021 annual results conference call on March 17, 2022

DGAP-News: MorphoSys AG / Key word(s): Annual results
10.03.2022 / 22:03
The issuer is solely responsible for the content of this announcement.

Conference call alert
Planegg/Munich, Germany, March 10, 2022

Invitation to the MorphoSys 2021 annual results conference call on March 17, 2022

MorphoSys AG (FSE: MOR; NASDAQ: MOR) will release its results for fiscal 2021 on March 16, 2022 at 9:00 p.m. CET (8:00 p.m. GMT; 4:00 p.m. EDT).

The MorphoSys management team will host a conference call and webcast on March 17, 2022 at 1:00 p.m. CET (12:00 p.m. GMT; 8:00 a.m. EDT) to present the results of the 2021 financial year and provide an outlook for 2022.

The conference call will begin with a presentation by the management team followed by a question and answer session.

A live webcast and slides will be available in the Investors section under “Upcoming Events and Conferences” on the MorphoSys website,

Dial-in number for the conference call (1:00 p.m. CET; 12:00 p.m. GMT; 8:00 a.m. EDT):

Germany: +49 69 201 744 220

For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers accessible from any geography)
Participant PIN: 41714570#

Please dial the number 10 minutes before the start of the conference.

A replay of the call will also be available on the company’s website following the live event.

About MorphoSys:
At MorphoSys, we are driven by our mission to give more life to people with cancer. As a global, commercial-stage biopharmaceutical company, we use breakthrough science and technology to discover, develop and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and its US operations are anchored in Boston, Massachusetts. To learn more, visit us at and follow us on Twitter and LinkedIn.

MorphoSys forward-looking statements
This communication contains certain forward-looking statements regarding the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which could affect the actual results, financial condition and liquidity, performance or achievements of MorphoSys. , or industry results, to be materially different from any historical or future results, financial and liquidity conditions, performance or achievements expressed or implied by such forward-looking statements. Furthermore, even if the results, performance, financial condition and liquidity of MorphoSys, as well as the development of the industry in which it operates are consistent with these forward-looking statements, they may not be predictive of the results or developments. in future periods. Among the factors that could cause differences are that MorphoSys’ expectations may be incorrect, inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, dependence of MorphoSys with respect to collaborations with third parties, the estimate of the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys’ annual report on Form 20-F and other documents filed with the United States Securities and Exchange Commission. Given these uncertainties, the reader is cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of the publication of this document. MorphoSys expressly disclaims any obligation to update any forward-looking statements in this document to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any such statement is based or which may affect the likelihood that results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information please contact:

10.03.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at

Comments are closed.